Parathyroid carcinoma (PC) is a rare but lethal endocrine malignancy and an uncommon cause of primary hyperparathyroidism that may lead to deleterious and sometimes fatal hypercalcemia. Surgery is the mainstay of treatment, but achieving a cure is rare, as 50% to 60% of patients with PC will develop recurrent disease even after margin negative resection. There are no known effective chemotherapeutic agents against PC, so patients with persistent disease have limited therapeutic options aimed only at palliating hypercalcemia. Overall survival remains low at 85% and 49% over 5 and 10 years, respectively \[[@B1], [@B2]\]. For this reason, there remains a pressing need to identify molecular drivers and potentially actionable pathways in PC carcinogenesis; however, these efforts have been hindered by low disease incidence and wide variation in pathologic criteria for PC diagnosis \[[@B3], [@B4]\].

Next-generation sequencing (NGS) has emerged as a powerful tool in cancer genomics, leading to a rapid increase in our knowledge of the genetic and epigenetic events involved in tumor formation and progression and identifying actionable mutations. The Cancer Genome Atlas (TCGA) has identified major genetic drivers of a number of human tumors using comprehensive genomic characterization and identified potential targets of therapeutic interest \[[@B5]\]. Due to its low incidence, PCs were not evaluated in these studies, so the genomic landscape of PC is still being defined. The Cancer Gene Census (TCGC) \[[@B6]\], a manually curated list of genes that are somatically mutated and causally implicated in human cancer by at least two independent reports, currently associates only two genes with PC: CDC73 and MEN1. These studies primarily involved cases of familial hyperparathyroidism-jaw tumor syndrome and familial isolated primary hyperparathyroidism and reported CDC73 and MEN1 as potential drivers of PC tumorigenesis \[[@B7]\]. Subsequent cohort studies of sporadic PC also implicated CDC73 as genomic driver of PC tumorigenesis \[[@B11]\]. PRUNE2, MTOR, and PIK3CA genes were also found to be mutated in PC in these studies, implicating aberrations in the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) as a potential candidate pathway for PC tumor initiation or progression \[[@B14]\]. However, more studies are needed to investigate the role of these and other genes and pathways in PC tumorigenesis.

Fresh or fresh-frozen tumor tissue is the preferred specimen for NGS, as this storage method minimizes exposures that compromise DNA integrity. However, access to fresh or fresh-frozen tissue specimens is limited due to storage logistics, and in rare tumors such as PC, formalin-fixed, paraffin-embedded (FFPE) tissue samples are an invaluable biobank and offer considerable opportunity for further genomic exploration of this disease. Concerns regarding DNA fragmentation and modification from formalin fixation are well documented and prove a substantial challenge in the widespread use of FFPE samples for high-throughput molecular characterization. However, the TCGA and others have recognized the unparalleled value of this tumor source, and recent studies demonstrating feasibility of reliable DNA sequencing using stored FFPE samples have generated uniform protocols for improved accuracy and spurred interest in their utilization \[[@B17], [@B18]\]. In this study, we present genomic characterization in 29 patients with sporadic PC using whole-exome sequencing of FFPE-extracted DNA.

1. Methods {#s7}
==========

A. Study Population and Data Collection {#s8}
---------------------------------------

We performed a retrospective analysis of all patients undergoing surgical resection at MD Anderson Cancer Center (MDACC) for a diagnosis of PC according to World Health Organization (WHO) diagnostic criteria \[[@B15]\] between 1990 and 2016. Clinical data, banked tumor, and blood samples were collected under institutional review board--approved protocols. An independent pathologist reviewed all slides to further strengthen clinicopathologic criteria for PC diagnosis. Patients with evidence of vascular invasion, local invasion, and distant metastasis were included in our analysis. Patients with parathyroid tumors of uncertain malignancy or atypical parathyroid neoplasms were excluded. Thirty-one patients who met stringent PC diagnostic criteria had available FFPE tumor tissue from primary, recurrent, or metastatic cancers constitute our study cohort. For each patient, three 10-μm sections of tumor were acquired. Primary PC was defined as PC by WHO diagnostic criteria without tumor recurrence after resection, recurrent PC was defined as local tumor recurrence after resection with curative intent, and metastatic PC was defined by pathologic or imaging confirmation of distant metastasis.

B. DNA Extraction {#s9}
-----------------

DNA extraction was performed by the Biospecimen Extraction Facility at MDACC. FFPE tumor tissue from primary, recurrent, or metastatic PC was subjected to DNA extraction optimized for FPPE tissues using the Qiagen QIAamp DNA FFPE Tissue kit. DNA was quantified using a NanoDrop spectrophotometer (OD 260 and 280) and Qubit™ dsDNA HS Assay (Thermo Fisher Scientific) with Qubit 2.0 fluorometer. Sample quality assessment was performed using the Fragment Analyzer High Sensitivity Genomic DNA Analysis Kit (Advanced Analytical). The ratio of single-nucleotide substitutions of the same type, C\>T (transitions), to single-nucleotide substitutions of a different nucleotide, A\>T (transversions), was calculated to measure the effect of C\>T artifact in each sample.

C. Whole-Exome Sequencing {#s10}
-------------------------

Whole-exome sequencing was performed by the Sequencing and Microarray Facility at MDACC using previously published methodology \[[@B19]\]. Briefly, libraries were prepared from Biorupter ultrasonicator (Diagenode)--sheared genomic DNA using the Agilent Technologies SureSelectXT Reagent Kit. Libraries were prepared for capture with 10 cycles of PCR amplification and then assessed for size distribution on the Fragment Analyzer using the High Sensitivity NGS Fragment Analysis Kit (Advanced Analytical) and quantity using the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific). Exon target capture was performed using the Agilent Technologies SureSelectXT Human All Exon V4 kit. Following capture, index tags were added to the exon-enriched libraries using 10 cycles of PCR. The indexed libraries were then assessed for size distribution and quantified using the Agilent Technologies 4200TapesStation and the Qubit dsDNA HS Assay Kit, respectively. Equal molar concentrations of libraries were multiplexed eight to nine samples per pool, and each pool was sequenced in one lane of the Illumina HiSeq4000 sequencer, using the 76nt paired end format.

D. Identification of Somatic and Germline Variants {#s11}
--------------------------------------------------

Sequence reads were aligned to human reference genome GRCh37 using BWA (version 0.7.9a). Variants were detected using VarScan v2.3.9 using the VARSCAN2 "mpileup2snp" function with the following parameters for variant calling and filtering: min-coverage 10, *P* value 0.01, min-freq-for-hom 0.9., and strategies for variant filtering to minimize false positives associated with common sequencing artifacts as previously described \[[@B20]\]. Variants were filtered based on exome capture regions, strand bias, *P* value, and coverage and annotated by ANNOVAR (version: Revision 521; human reference: *hg19*) \[[@B21]\]. As the matched normal samples were not available, a pooled virtual normal sample was built as described by Hiltemann *et al.* \[[@B22]\] using all available germline variants (including non-PASS) of the 1000 Genomes Project (phases 1 and 3) \[[@B23], [@B24]\], the non-TCGA Exome Aggregation Consortium (ExAC) database (r0.3.1) \[[@B25]\], and 11 large dbGap studies \[[@B26]\] that are not related to cancer (phs000254, phs000291, phs000473, phs000474, phs000653, phs000655, phs000687, phs000693, phs000711, phs000744, and phs000827). Without normal matched samples, we were not able to distinguish somatic from private or rare germline variants, so they were analyzed together to identify potential driver mutations. Indels were excluded from analysis, as indel calls are more difficult to make, and the use of a single caller may introduce false-positive data.

E. Computational Analysis of the Genetic Variants {#s12}
-------------------------------------------------

The functional impact of each variant was estimated by the Evolutionary Action (EA) method. The EA scores of human variants are available from the EA server at <http://mammoth.bcm.tmc.edu/uea/>. The EA of a missense mutation is calculated as a product of two terms that represent the evolutionary sensitivity of the mutated position and the magnitude of the amino acid substitution, both of which can be estimated from evolutionary data \[[@B27]\]. The final EA score ranges from 0 (no fitness change) to 100 (complete loss of function), such that they indicate the predicted percent of fitness loss.

To assess the separation of somatic or private germline variants from known germline variants in PC, we used purifying selection pressure *λ* \[[@B28]\]. Germline variants have been under stronger selection pressure than somatic variants, resulting in substantially steeper exponentially decaying distributions of EA scores. The coefficient *λ* of the decays, calculated through regression analysis on 10 equidistant bins of EA values, can be used to assess the quality of germline and somatic mutations \[[@B28]\]. As a reference, we used somatic variants from 20 cancer types (downloaded in October 2014 as 54 mutation annotation format files from <https://tcga-data.nci.nih.gov>) and germline variants from the 1000 Genomes Project (phase 3 dated May 2015 downloaded from [ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/](http://ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/)).

For variants of specific genes or pathways, we identified selection patterns by comparing the distributions of EA scores of variants with random nucleotide changes on the corresponding sequence using the Kolmogorov-Smirnov (K-S) test. The K-S test is a nonparametric test of the equality of continuous, one-dimensional probability distributions. The *P* values were calculated for the null hypothesis that the sample was drawn from the reference distribution, quantifying the maximum distance between the cumulative distributions.

2. Results {#s13}
==========

A. Quantity and Quality of DNA Extraction {#s14}
-----------------------------------------

A total of 31 unique FFPE samples were subjected to successful DNA extraction with a median yield of 7.8 µg/sample \[interquartile range (IQR) 4.2 to 16.0\] and a median A260/280 ratio of 2.0 (IQR 1.9 to 2.01). FFPE samples ranged from 1 to 26 years of storage. Two of 31 tissues (7%) had poor DNA quantity and quality and were excluded from analysis. The remaining 29 unique patient samples comprise the study cohort and underwent successful sequencing defined as having a nonfailed final library \>200 bp (median 295 bp; IQR 205 to 368) covering ≥50% of the target at 20 times. Of these 29 patients, 16 patients had primary sporadic PC that was adequately treated with initial surgical resection, 6 patients had recurrent local disease, and 7 patients had metastatic PC (4 patients with lung metastases, 1 patient with bone metastasis, 1 patient with liver metastasis, and 1 patient with both bone and lung metastases). Their clinical characteristics are briefly summarized in [Table 1](#T1){ref-type="table"} \[[@B27], [@B29]\]. The median ratio of transitions to transversions, a measure of DNA chemical cross-linking and modification, was 2.09 (IQR 2.06 to 2.11), well within the expected range of high-quality FFPE-extracted DNA and comparable to ratios reported in fresh-frozen tissues \[[@B17]\]. Genomic data was deposited into the National Center for Biotechnology Information Database of Genotypes and Phenotypes (NCBI dbGaP) \[[@B30]\].

###### 

Clinical and Pathologic Diagnostic Features of Patients With Sporadic PC Who Comprise the Study Cohort With Somatic or Private Germline Variants Called, Allelic Fraction, and Evolutionary Action Score

  Patient Identification Number   Clinical Course       WHO Diagnostic Criteria                                      Tumor Size, cm   Current Status   Serum Ca at Dx   PTH at Dx   Gene       Variant   Allele Fraction   EA
  ------------------------------- --------------------- ------------------------------------------------------------ ---------------- ---------------- ---------------- ----------- ---------- --------- ----------------- -------
  001                             Primary PC            Vascular invasion                                            1.6              DOC              12.3             1000        TP53       K132N     0.371             92.22
  002                             Recurrent PC          Vascular invasion, soft tissue extension                     8                DOC              Unknown          Unknown     KMT2B      R1771Q    0.259             99.97
  SUN2                            W582C                 0.833                                                        90.88                                                                                                 
  NUP107                          S167L                 0.706                                                        83.85                                                                                                 
  TP53                            R181C                 0.827                                                        54.85                                                                                                 
  XAB2                            D253N                 0.406                                                        53.53                                                                                                 
  003                             Primary PC            Soft tissue extension                                        2.5              NED              14.3             507         LATS2      K793M     0.333             86.19
  SYNE1                           I3456M                0.563                                                        40.29                                                                                                 
  004                             Recurrent PC          Vascular invasion, soft tissue extension                     2.5              DOD              16               1200        CDC73      W32X      0.817             STOP
  005                             Metastatic PC         Vascular invasion, soft tissue extension, lung metastasis    5                AWD              13.4             659         MSH2       Q545X     0.846             STOP
  GLI3                            Q710X                 0.286                                                        STOP                                                                                                  
  NF1                             R1748X                0.756                                                        STOP                                                                                                  
  POLR2E                          A102V                 0.395                                                        57.98                                                                                                 
  006                             Primary PC            Vascular invasion, soft tissue extension                     1.5              DOD              13.6             143         VCAN       G3102S    0.578             78.18
  ERC1                            N266S                 0.549                                                        44.06                                                                                                 
  007                             Recurrent PC          Soft tissue extension                                        2.1              NED              16               700                                                
  008                             Metastatic PC, lung   Vascular invasion, soft tissue extension, lung metastasis    5                AWD              16               1256        ARID1B     M923K     0.388             93.07
  RFC5                            R215T                 0.323                                                        59.82                                                                                                 
  009                             Primary PC            Vascular invasion, soft tissue extension                     3.5              NED              12.1             120         KMT2C      R4523S    0.214             77.69
  010                             Primary PC            Soft tissue extension                                        2                NED              15.3             536                                                
  011                             Primary PC            Soft tissue extension                                        1.8              NED              11.3             800                                                
  012                             Primary PC            Vascular invasion                                            1                NED              10.9             67          MEN1       G230X     0.88              STOP
  BRCA2                           S3133L                0.481                                                        79.58                                                                                                 
  FANCL                           L254V                 0.436                                                        53.8                                                                                                  
  013                             Recurrent PC          Vascular invasion, soft tissue extension                     3.5              AWD              17               1707        KMT2D      R2830Q    0.404             59.73
  014                             Metastatic PC         Vascular invasion, soft tissue extension, liver metastasis   4                AWD              13.2             298         CENPF      R3094X    0.324             STOP
  TSC1                            R228X                 0.638                                                        STOP                                                                                                  
  TP53                            R306X                 0.806                                                        STOP                                                                                                  
  PTPRB                           R1844W                0.292                                                        78.17                                                                                                 
  POLR2L                          A34T                  0.22                                                         66.12                                                                                                 
  RAD50                           S1244C                0.264                                                        60.21                                                                                                 
  RAD50                           I1227M                0.222                                                        55.23                                                                                                 
  015                             Metastatic PC         Soft tissue extension, lung metastasis, bone metastasis      3                DOD              18               620         SYCP2      P495L     0.318             87.9
  016                             Primary PC            Soft tissue extension                                        2.3              NED              10.6             256         BRAF       G469A     0.4               61.77
  017                             Primary PC            Vascular invasion, soft tissue extension                     3                NED              11.5             359                                                
  018                             Metastatic PC         Vascular invasion, soft tissue extension, bone metastasis    2.5              DOD              14.5             2801        ATM        L1327X    0.423             STOP
  AKAP9                           E341V                 0.511                                                        46.94                                                                                                 
  019                             Primary PC            Vascular invasion, soft tissue extension                     4                NED              12               140         MEN1       H438P     0.822             93.03
  020                             Primary PC            Vascular invasion, soft tissue extension                     4                NED              20.5             2203        PSMC3IP    K128X     0.539             STOP
  SYNE1                           E5956G                0.528                                                        77.53                                                                                                 
  021                             Primary PC            Soft tissue extension                                        3.2              NED              11.8             114                                                
  022                             Primary PC            Soft tissue extension                                        2                NED              12.6             137                                                
  023                             Metastatic PC         Vascular invasion, soft tissue extension, lung metastasis    1.5              AWD              13.7             698         CDC73      R76X      0.413             STOP
  CENPF                           S1780X                0.237                                                        STOP                                                                                                  
  CTNNB1                          Q72X                  0.278                                                        STOP                                                                                                  
  KDM5C                           G536R                 0.721                                                        95.87                                                                                                 
  CDC73                           Y55C                  0.377                                                        89.54                                                                                                 
  024                             Metastatic PC         Vascular invasion, soft tissue extension, lung metastasis    3                DOD              15.3             7200                                               
  025                             Primary PC            Soft tissue extension                                        Unknown          NED              13.5             213                                                
  026                             Recurrent PC          Soft tissue extension                                        3.7              AWD              Unknown          133         KIAA1549   W1853X    0.351             STOP
  027                             Primary PC            Vascular invasion, soft tissue extension                     3.5              NED              12.1             Unknown     AKAP9      V1595L    0.473             54.46
  028                             Recurrent PC          Soft tissue extension                                        1.1              AWD              Unknown          Unknown     CDC73      Y55X      0.311             STOP
  ERBB4                           Q1260X                0.447                                                        STOP                                                                                                  
  029                             Primary PC            Vascular invasion, soft tissue extension                     2                DOC              13.2             567                                                

Clinical Course: primary PC was defined as parathyroid cancer by WHO diagnostic criteria without tumor recurrence after resection, recurrent PC was defined as local recurrence after curative resection, and metastatic PC was defined by pathologic or imaging confirmation of distant metastasis. WHO Diagnostic Criteria: the WHO states that the diagnosis of PC should limited to tumors with evidence of invasion into adjacent soft tissue, organs, or structures, invasion into capsular or extracapsular blood vessels or perineural spaces, and to patients with documented metastasis \[[@B29]\]. Tumor Size: primary parathyroid tumor size at diagnosis reported in centimeters. Current Status: alive with disease (AWD); died of other causes (DOC); died of disease (DOD); and alive with no evidence of disease (NED). Serum Ca at Dx: serum calcium (Ca) levels at diagnosis (Dx) reported in milligrams per deciliter. PTH at Dx: serum parathyroid hormone (PTH) level at Dx reported in picograms per milliliter. Allele Fraction: the relative frequency of the gene variant expressed as a fraction of the tumor chromosomes that that carry that allele. EA: a measure of fitness effect of the variants in each gene as calculated by the EA equation \[[@B27]\].

B. Validity of Somatic Calls {#s15}
----------------------------

Without normal matched samples, we were unable to distinguish between somatic and rare germline variants, so the number of these variants might be higher than the number of the true somatic variants. As such, the mutations are reported as PC somatic or private germline mutations. We assessed for each sample from our cohort whether the number of somatic or private germline mutations and their distribution of fitness effects were consistent with observations from other cancer types and from two previously published cohorts of PC samples, the PC dataset from Yu *et al.* \[[@B14]\] that was obtained from Pandya *et al*. \[[@B16]\]. In our 29 samples, we found a range of 18 to 144 missense mutations per sample. This number of missense variants is comparable to that seen in other datasets, and the lambdas are similar to those of TCGA, suggesting that our data are consistent with what is expected and that the analysis is valid ([Fig. 1A](#F1){ref-type="fig"}). The sample median was 49 missense mutations, which was intermediate to the medians of the two smaller published cohorts that had 21 and 84 missense mutations, respectively. Also, both extreme samples of our cohort were within the ranges of the other two parathyroid cohorts. To estimate the extent of germline variants in our somatic calls, we calculated the purifying selection pressure (*λ*) \[[@B28]\]. The missense somatic or private germline mutation calls in our cohort had a distribution of *λ* values that was indistinguishable from TCGA variants ([Fig. 1B](#F1){ref-type="fig"}) and from the somatic calls in the published PC cohorts. In contrast, the distributions of *λ* values for the variants we called germline were within and higher than the range for germline variants from the 1000 Genomes Project, which is higher and not overlapping with the range of somatic variants. These data show that even without matched normal samples, we could identify a group of somatic and private germline PC variants that have consistent features with the somatic variants of two prior PC cohorts and other cancer types. These variant calls and their corresponding allelic fractions (AFs) are summarized per patient in [Table 1](#T1){ref-type="table"} \[[@B27], [@B29]\].

![Somatic variant calls. (A) The average number of somatic missense mutations per sample for the reported PC cohort (red), the previously published PC cohorts (brown), and 14 cohorts of other cancer types (black) obtained from the TCGA portal. (B) The selection constraints index *λ* for somatic (red) and germline (blue) calls of the reported PC cohort (solid bars), compared with somatic variants of TCGA and germline variants of the 1000 Genomes Project, respectively (dotted bars).](js.2018-00043f1){#F1}

C. Candidate PC Driver Genes Identified {#s16}
---------------------------------------

We tested whether PC somatic and private variants can indicate genes under positive selection with no bias to the current knowledge of cancer driver genes. We estimated the fitness effect of the variants in each gene with the EA equation \[[@B27]\] and asked whether the distribution of EA scores is different from the distribution of random nucleotide changes. We considered 85 genes that harbored at least two somatic variations in our PC cohort, ignoring 1178 genes that had only a single nonsynonymous variation. Seven genes had a *P* value ≤0.05 by K-S test; only *CDC73* remained significant after accounting for multiple testing ([Supplemental Table S1](#sup1){ref-type="supplementary-material"}). *CDC73* and *MEN1* are the only genes associated with parathyroid tumors based on somatic mutation data, according to TCGC \[[@B6]\], which were prioritized as first and fifth in this analysis (K-S *P =* 0.002 and 0.03, respectively). *C9orf37*, *AGFG2*, *CENPF*, and *FSIP2* had *P* values \<0.05. Of these, centromere protein F (*CENPF* gene) plays a critical role in chromosome segregation during mitosis \[[@B31]\], and its expression levels have been associated with prostate cancer \[[@B32]\], hepatocellular carcinoma \[[@B31]\], and esophageal squamous cell carcinoma \[[@B33]\], suggesting it could be also implicated in PC. The genes with the most mutations in the parathyroid tumors (RGS3 and OSTC with six mutations each) had no bias to high impact (*P* \> 0.8), and they have not been associated with any cancer type in TCGC. These data suggest that our approach to consider the fitness impact of somatic mutations can help in prioritizing candidate genes, although the discovery of PC driver genes might be limited by the small number of somatic mutations per gene.

Next, we asked whether genes with nonsignificant K-S *P* values may yet have potential to be driver genes of PC based on nonrandom functional relationships with top prioritized genes. A total of 39 genes with a *P* value \<0.5 were significantly enriched in mutual protein-protein interactions according to the String v10.5 database (*P* = 1.9 × 10^−3^ for links with confidence ≥0.15; [Fig. 2A](#F2){ref-type="fig"}), indicating a significant functional relationship among these genes. When 20 additional genes with a bias to high or intermediate EA scores typical of tumor suppressor and oncogene mutations were included in network interaction analysis, the enrichment in gene interactions remained significant (*P* = 4 × 10^−4^ for links with confidence ≥0.15; [Fig. 2B](#F2){ref-type="fig"}). In addition to *CDC73* and *MEN1*, several genes strongly interacted ([Fig. 2](#F2){ref-type="fig"}), including seven genes found in TCGC \[(*TP53*, *AKAP9*, *KIAA1549*, *TSC1*, *ERC1*, *KMT2D* (*MLL2*), and *KMT2C* (*MLL3*)\] and six others (*RAD50*, *CENPF*, *NUP107*, *SYNE1*, *LATS2*, and VCAN), suggesting a potential role of these genes in parathyroid carcinogenesis.

![Protein interactions according to the String v10.5 database. The strength of the links indicates the confidence of association. Links with confidence ≥0.15 are shown. (A) Thirty-eight of the 39 genes with K-S *P* value ≤0.5 were able to map on the String network. (B) Fifty-seven of 59 genes with bias to high or intermediate EA scores were able to map on the String network.](js.2018-00043f2){#F2}

D. Pathway Analysis and Known Driver Selection {#s17}
----------------------------------------------

Using pathways from the Reactome database v49 \[[@B34], [@B35]\], we grouped the mutations of 7498 genes into 1580 pathways and their possible subpathways. We compared EA score distributions of each mutation set to random nucleotide changes and calculated the *P* values and the corrected for multiple test *q* values for each mutation set. The three highest-ranked sets of mutations implicated a total of 24 mutations across 16 genes that were key regulators of the *β*-catenin--TCF transactivating complex, meiosis, and DNA repair pathways ([Fig. 3](#F3){ref-type="fig"}). These 16 genes were enriched for TCGC members (*P* = 1.2 × 10^−5^) and positively identified the known PC drivers *CDC73* and *MEN1* in the top-ranked pathway. The DNA repair gene set, comprised of nine genes including *ATM*, *BRCA2*, *MSH2*, and *RAD50*, genes known to be drivers in other cancer types \[[@B36]\] but not previously associated with PC. Twelve of the 16 genes were affected by only a single mutation in the cohort, three genes (*MEN1*, *SYNE1*, and *RAD50*) were affected by only two mutations, and one gene (*CDC73*) by four mutations; however, when viewed as a whole, these three pathways were mutated in 45% of the patients. These data suggest that these functionally related genes likely represent PC drivers.

![Gene pathways under positive selection in PC. (A) Formation of the *β*-catenin, (B) meiosis, and (C) DNA repair gene pathways of the Reactome database were found to be nonrandomly mutated in patients with PC. Nonsynonymous mutations are binned in deciles by their EA score. Higher scores indicate loss of function, whereas intermediate scores indicate gain of function or function separation. Absolute counts of mutations in each bin are represented by the height of the bin. Each component gene is represented by a color, and plots are labeled with the Reactome pathway associated with the gene set.](js.2018-00043f3){#F3}

We further tested whether grouping the mutations of known cancer driver genes can reveal selection patterns. We considered 213 genes that have been associated with any cancer type because of their somatic mutations, according to TCGC \[[@B6]\] ([Supplemental Table S2](#sup1){ref-type="supplementary-material"}). In our PC cohort, we observed 10 silent (S), 30 missense (M), and 11 nonsense (N) mutations in these 213 genes, compared with 559 S, 1289 M, and 54 N mutations in the rest of the genes ([Supplemental Table S3](#sup1){ref-type="supplementary-material"}). The increase in N/S ratio was \>10-fold ([Fig. 4A](#F4){ref-type="fig"}), suggesting that almost all CGC genes with any nonsense mutations, *CDC73*, *MEN1*, *TP53*, *NF1*, *ATM*, *TSC1*, *CTNNB1*, *ERBB4*, and *MSH2*, are likely PC driver candidates.

![Somatic mutations of known cancer drivers show selection patterns in parathyroid tumor variants. (A) The ratios of missense-to-silent and nonsense-to-silent somatic parathyroid tumor variants for 213 cancer-associated genes (blue) and for the rest of the genes (orange). (B) The distribution of EA fitness scores for missense variants normalized by the number of silent mutations for the 213 cancer-associated genes (blue bars) and for the rest of the genes (orange line). (C) Gene-interaction links (String v10.5 database; link confidence \>0.4) among *TP53*, *CDC73*, and *MEN1* with genes that have impactful variants in parathyroid tumors but they were not listed in TCGC.](js.2018-00043f4){#F4}

We also compared the AF of the potential candidate drivers in [Table 1](#T1){ref-type="table"} \[[@B27], [@B29]\], the passenger somatic or private variants, and the germline variants to further support our proposed candidate driver variants (Fig. S1). The N/S ratio of CGC genes was increased by 43% compared with the rest of the genes, and this bias was mostly due to missense mutations with high EA ([Fig. 4B](#F4){ref-type="fig"}), which occurred on genes *TP53*, *MEN1*, *ARID1B*, *KDM5C*, *PTPRB*, and *CDC73*. Common oncogenic mutations have been listed as hotspot driver mutations in COSMIC, and we only found one such mutation: BRAF G469A (EA score of 62). To identify potential candidate driver genes among those not listed in TCGC, we considered genes with nonsense or high EA mutations in parathyroid tumors, and they are associated to *CDC73*, *MEN1*, and *TP53*. From 21 genes that meet these criteria ([Fig. 4C](#F4){ref-type="fig"}), *GLI3* (Q710X) and *MLL4* (R1771Q) are directly linked to *CDC73* and *MEN1*, respectively, so they too may be specific candidate drivers of PC.

E. Germline Variant Analysis {#s18}
----------------------------

To identify germline variants of patients with PC, we considered their relative impact compared with the general population. We used ExAC data \[[@B25]\] as reference. Gene impact was measured as a percentile rank of the mutation burden defined as the average EA score of the gene variants divided by the logarithm of the variant allelic frequency. Genes with the largest difference in mutation burden for the two cohorts (≥60%) were identified as potential PC-associated genes through germline variants. Despite the small number of PC germline variants (three to four variants per gene on average), genes impaired more severely in PC than in the general population were enriched in the Kyoto Encyclopedia of Genes and Genomes pathway annotations of MAPK signaling, T-cell receptor signaling, chronic and acute myeloid leukemia, and pathways in cancer (*P* values 0.002 to 0.02; [Fig. 5A](#F5){ref-type="fig"}). In contrast, genes impaired less severely in PC than in the general population were enriched in immune response pathways, including a Kyoto Encyclopedia of Genes and Genomes annotation of autoimmune thyroid disease (*P* value of 10^−7^; [Fig. 5B](#F5){ref-type="fig"}). Together, these data suggest that germline variants may play a role in developing PC.

![Genes with different germline mutation burden between patients with parathyroid cancer and general human population. (A) Genes that harbor germline variants with higher impact in patients with PC than in individuals of the ExAC database. (B) Genes that harbor germline variants with lower impact in patients with parathyroid cancer than in individuals of the ExAC database.](js.2018-00043f5){#F5}

3. Discussion {#s19}
=============

Our understanding of PC carcinogenesis and the role of genetic and epigenetic factors in its tumor formation and progression have been severely limited by the low incidence of disease, with \<100 new cases per year diagnosed in the United States \[[@B1], [@B40]\]. Although the TCGA and others have amassed large volumes of genetic data on a variety of tumors, PC has been largely ignored in efforts to study the genomic basis of cancer due to poor availability of fresh-frozen tissue. In this study, we present a genomic study of PC with whole-exome sequencing of 29 sporadic PC tumors using DNA extracted from FFPE tumor specimen with 93% successful whole-exome sequencing assay results and with acceptable DNA quantity and quality. Furthermore, the stated transition to transversion ratio suggests that fixation artifacts resulting in C\>T substitutions are unlikely to have a major impact on our genomic findings. We identified potential candidate driver somatic variants and genes, and we compared the results with two independently published cohorts of PC totaling 18 exomes \[[@B14], [@B16]\]. We prioritized somatic and private germline variants with the EA equation and compiled a list of 35 genes that were prominent in one or more of the analyses we performed (single-gene analysis and gene interactions, gene pathway analysis, impactful mutations of TCGC genes, and interactors of *CDC73* and *MEN1*) ([Table 2](#T2){ref-type="table"}). Intriguingly, this table lists a considerable number of large genes that are often present in recurrent analyses of other cancer types. Although false positives are expected to be seen in large genes due to higher probability for mutation, the performed analyses, especially the nonsense mutations and pathways analyses, also favor the discovery of these large genes. Only 8 of these 35 genes were previously reported with any somatic mutation in previous PC cohorts, of which only 5 genes (*CDC73*, *AKAP9*, *NUP107*, *SYNE1*, and *VCAN*) had large enough EA impact (nonsense, frameshift indels, and missense with EA \>30) as expected for driver mutations.

###### 

Potential Candidate Driver Genes of Sporadic Parathyroid Cancer, Their Functional Pathways, and the Somatic or Private Germline Mutations Observed in the Current Cohort and Somatic Variants From Previous Studies

  Gene           Function Pathways (PathCards)                                 Somatic Variants, Study Cohort of N = 29 (EA)
  -------------- ------------------------------------------------------------- -----------------------------------------------
  AKAP9          RET signaling and Regulation of PLK1 Activity                 **E341V (**47**)**; **V1595L (54)**; T2427T
  ARID1B         Activation of the ESR1/SP pathway                             **M910K (88)**
  ATM            DNA Double-Strand Break Repair                                **L1327X**
  BRAF           Trk receptor signaling and mTOR Pathway                       **G496A (62)**
  BRCA2          DNA Double-Strand Break Repair                                **S3133L (80)**
  CDC73          Signaling by Wnt and Signaling by Hedgehog                    **W32X**; **Y55X**; **R76X**; **Y55C (90)**
  CENPF          FOXM1 transcription factor and Regulation of PLK1 Activity    **S1780X**; **R3094X**
  CTNNB1         Development VEGF and Endothelin-1/EDNRA signaling             **Q72X**
  ERBB4          GPCR Pathway and RET signaling                                **Q1260X**
  ERC1           IL-1 and NF-*κ*B signaling pathways                           **N266S (**44**)**; S969Y (29)
  FANCL          Fanconi anemia and DNA repair                                 **L254V (54)**; F36F
  GLI3           Wnt Signaling and Hedgehog Pathway                            **Q710X**
  KDM5C          Activated PKN1 and Chromatin organization                     **G536R (96)**
  KIAA1549       HIV Life Cycle and Oncogenic MAPK signaling                   **W1853X**; A905T (27)
  KMT2B (MLL4)   Lysine degradation and PKMTs methylate histone lysines        **R1771Q (100)**
  KMT2C (MLL3)   Lysine degradation and Activated PKN1                         L3483S (24); **R4523S (78)**
  KMT2D (MLL2)   Lysine degradation and Signaling by Wnt                       P610A (19); **R2830Q (60)**
  LATS2          Hippo signaling and Signaling by GPCR                         A428T (22); **K793M (86)**
  MEN1           Transcriptional activity of SMADs and Signaling by Wnt        **G230X; H438P (93)**
  MSH2           Mismatch repair and Platinum drug resistance                  **Q545X**
  NF1            Development VEGF signaling and RET signaling                  **R1748X**
  NUP107         HIV Life Cycle and Transport of the SLBP mRNA                 **S167L (84)**; **L301M (**39**)**
  POLR2E         HIV Life Cycle and Formation of HIV elongation complex        **A102V (58)**
  POLR2L         HIV Life Cycle and Formation of HIV elongation complex        **A34T (66)**
  PSMC3IP        Meiosis and Cell Cycle, Mitotic                               **K116X**
  PTPRB          Innate Immune System and Activation of cAMP-Dependent PKA     **R1754W (91)**
  RAD50          DNA Double-Strand Break Repair                                **I1227M (55); S1244C (60)**; L1211L; I1212I
  RFC5           DNA Double-Strand Break Repair and Translesion synthesis      **R215T (60)**
  SUN2           Cell Cycle, Mitotic and Meiosis                               **W582C (91)**
  SYCP2          Cell Cycle, Mitotic and Meiosis                               **P495L (88)**
  SYNE1          Cell Cycle, Mitotic and Meiosis                               **I3456M (**40**)**; **E5956G (78)**; L3447L
  TP53           IGF-1 receptor signaling and DNA Double-Strand Break Repair   **R306X; K132N (92)**; **R181C (55)**; T125T
  TSC1           IGF-1 receptor signaling and RET signaling                    **R177X;** V25M (10)
  VCAN           Phospholipase-C Pathway and Chondroitin sulfate metabolism    P2996T (32); **G3102S (78)**
  XAB2           mRNA Splicing and TC Nucleotide Excision Repair               **D253N (54)**

The mutual interactions of the genes are according to STRING v10.5 (for link confidence \>0.15). Bold text indicates variants predicted to have high impact (EA score is above 30).

Abbreviations: GPCR, G-protein--coupled receptor; PKA, protein kinase A; PKMT, protein lysine methyltransferase; TC, transcription coupled; VEGF, vascular endothelial growth factor.

*CDC73* variants were underrepresented in the current study, with only three patients found to have truncating CDC73 mutations. This may be because indel data were excluded from our analysis. The analysis was limited to single nucleotide variant data because indel calls are more difficult to make, and the use of a single caller may introduce false-positive data. Additionally, exon 1 of the CDC73 gene is known to have large GC repeats that are not well covered with NGS. Exon 1 is known to harbor a notable proportion of known CDC73 somatic mutations \[[@B13]\]. Other studies have identified five frameshift indels of CDC73 of 18 cases, suggesting that a substantial number of CDC73 mutations were not captured in our study and represent a considerable limitation. Further Sanger analysis of exon 1 may result in more calls. Notably, no *TP53* mutations were reported in either prior reported PC cohorts. Additionally, no somatic or private germline mutations were found in genes PRUNE2, MTOR, PIK3CA, and CCND1 in our study cohort. Although copy-number variations in CCND1 have been previously reported in PC, we did not evaluate copy number in the current study, and so the impact of CCND1 in this PC cohort remains unknown \[[@B14]\]. *TSC1* and *NF1* variants were observed, each with AFs \>0.5 (0.638 and 0.756, respectively), suggesting loss of heterozygosity. Both *TSC1* and *NF1* are critical negative regulators of *mTOR* with loss of heterozygosity leading to *mTOR* signaling activation and proliferative dysregulation \[[@B41], [@B42]\]. The presence of these two somatic variants further implicate the PIK3CA-mTOR-AKT axis in sporadic PC tumorigenesis and support the study and use of available therapeutics that target these pathways (such as everolimus) in this patient population.

*CTNNB1* was also found to be mutated in our study. *CTNNB1* is known to be an oncogene, and it is therefore surprising to have a truncation mutation seen in PC. The *CTNNB1* variant Q72X was called in both sequenced samples of that individual with 15 out of 54 and 23 out of 57 reads supporting the variant call. *CTNNB1* truncations have been observed in 52 of 7307 tumor samples according to the COSMIC database. Although *CTNNB1* is a 781-amino-acid--long protein, these truncations were not randomly distributed in the sequence with the majority of the truncation mutations, 34 (65%) occurring within the first 100 amino acids (13% of the protein), including Q72X. This suggests that cancer cells may prefer to have an early sequence truncation of *CTNNB1* rather than a late one, for reasons we do not understand.

The differences in somatic variants observed between prior PC genomic cohorts illustrate the need for obtaining more sequencing data of parathyroid tumors to understand the underlying biological mechanisms that cause PC beyond the role of *CDC73* deactivation. Our list of 35 potential candidate genes is a major step toward this goal; however, further validation is needed. Some of these 35 potential PC candidate genes also contained impactful germline variant that might be disease risk factors, but, due to sample size and data structure limitations, did not yield notable associations. Notably, no previously reported germline variants were found in *CDC73*, and only three common silent variants were found in *MEN1*. The group of 35 genes had 181 nonsynonymous germline variants collectively, of which only 58 had sufficiently large EA impact (EA ≥30) to be considered as potential PC driver variants ([Table 2](#T2){ref-type="table"}). Perhaps of most interest are two *TP53* variants (R337C and R248W with EA scores of 63 and 89, respectively), both of which are frequent cancer driver mutations according to COSMIC \[[@B43]\] (although annotated as germline variants because of their allele frequency of 8 × 10^−6^ in ExAC, they may be somatic variants in patients with PC), and three *RAD50* variants (T191I, V315L, and R327H with EAs of 58, 61, and 42, respectively). Other genes with potentially interesting germline mutations include *ATM*, *GLI3*, *KIAA1549*, *KMT2B*, *KMT2C*, and *SUN2*. Beyond these 35 genes, we also considered those with higher or lower impact in PC compared with the general population as represented by the ExAC database.

We acknowledge several limitations in our study. First, matched germline control samples were not available for analysis given the retrospective nature of this study. For this reason, we could not distinguish between somatic and private germline mutations, and so these variants were analyzed together. Fresh-frozen tissue is the gold standard for DNA isolation and sequencing, but in this rare tumor, prospective studies to amass substantial numbers of fresh-frozen samples are not feasible without wide-scale national and international collaborations. Retrospective studies using available FFPE tissue offer a good alternative for genomic insight in this disease. The use of FFPE samples for high-throughput parallel sequencing has not been widely adopted due to concerns for high rates of nonreproducible DNA sequence alterations from formalin cross-linking causing artificial C\>T transitions \[[@B44], [@B45]\]. However, several recent publications have reported feasibility and clinical utility of NGS on FFPE tissue using the methodology used in our present study with high concordance between matched fresh-frozen and FFPE with successful sequencing tied more to DNA extraction quantity and quality \[[@B17], [@B18], [@B46]\]. Carrick *et al.* \[[@B17]\] reported the ratio of transitions to transversions increased with storage time, these ratios were only marginally higher in FFPE samples, even in tissue stored up to 32 years, when compared with fresh-frozen tissue. Similarly, Spencer *et al*. \[[@B46]\] found high concordance between NGS genomic analysis from matched fresh-frozen and FFPE tissue and concluded that though there is a detectable effect on DNA after FFPE preservation, this effect has a negligible impact on NGS with appropriate extraction and sequencing optimization. In the current study, the median time of FFPE tissue storage was 11 years (IQR 5 to 16), and DNA extraction resulted in acceptable transition to transversion ratios with low library failure rates (7%) and good coverage statistics.

We used a single-algorithm VarScan v2.3.9 to make variant calls. VarScan v2.3.9 is a well-validated pipeline variant calling that employs strategies to minimize false positives associated with common sequencing-related and alignment-related artifacts with high sensitivity and specificity \[[@B20]\]. However, no consensus calls were made using multiple pipelines, and manual review of each variant call was not performed. As such, there is potential for false-positive or false-negative calls in this analysis. Sanger analysis was not performed in this study, so that areas of the genome susceptible to be missed by NGS (*i.e.*, large deletions and high GC content) may not be well captured and represent another limitation of this study.

Though a sample size of 29 tumors is substantial for sporadic PC given its very low incidence, genes with low frequency that may carry significance in sporadic PC tumor initiation and progression are likely not captured in this analysis. Because sequencing was carried out in tumor samples only, and though common variants were filtered, it is possible some of the mutations we identified in the expansion cohort ([Supplemental Table S1](#sup1){ref-type="supplementary-material"}) are rare or private germline variants rather than somatic mutations. Due to restricted sample availability, we were unable to generate genomic data in other platforms such as gene expression profiling. The genetic alterations identified through exome sequencing would be even better interpreted if integrative data analysis could have been performed with genomic data based on multiple platforms, as demonstrated in TCGA. Gene expression data would allow us to corroborate and extend copy number variation analysis results such as CCND1 amplification. Nevertheless, the current study represents a robust genomic sequencing effort and analysis for an extremely rare malignancy. Our results have indeed revealed important insights into the genetic landscape of PCs. The phosphatidylinositol 3-kinase/AKT/mTOR pathway is again identified as a potentially major oncogenic pathway in sporadic PC. In our study, both *TSC1* and *NF1* variants have AFs \>0.5 (0.638 and 0.756, respectively), which indicate loss of heterozygosity. This further implicates the PIK3CA/AKT/mTOR axis in sporadic PC tumorigenesis and adds to the growing body of data that support the use of everolimus in metastatic PC.

In summary, we studied the genetic variations of 29 PCs to identify candidate driver genes. Although currently this is the largest available cohort, the relatively small number of samples compared with other cancer types is a limiting factor to discover driver genes with high confidence. To enhance our ability to discover genes, we accounted for the fitness impact of the genetic variations using the EA equation. EA predictions were shown to correlate with experimental and clinical data better than other approaches \[[@B47]\] and have been used before to identify driver genes in hepatocellular carcinoma \[[@B48]\] and to separate patient survival in head and neck cancer \[[@B49]\] and colorectal liver metastases \[[@B50]\]. Our study identified, besides the known PC driver genes *CDC73* and *MEN1*, 33 additional candidates, most associated with other cancer types. Germline variants may predispose to PC, especially variants in genes associated with MAPK signaling, T-cell receptor signaling, and immune response. Our findings are tempered by the inherent molecular artifacts introduced during preservation of FFPE tissue and the lack of matched germline DNA available for analysis. Additionally, variant calls were made using only a single algorithm and as such, may include false-positive or false-negative calls. Nevertheless, these data provide insight into the biology of sporadic PC and open ground for further genetic and therapeutic studies to better treat this disease.
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